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Understanding  and  controlling  powder  de-agglomeration  is  of  great importance  in the  development
of  dry powder  inhaler  (DPI)  products.  Dry  dispersion  laser  diffraction  measures  particle  size  readily
under  controlled  dispersing  conditions,  but has  not  been  exploited  fully  to  characterise  inherent  pow-
der  dispersibility.  The aim  of the  study  was  to  utilise  particle  size-dispersing  pressure  titration  curves
to  characterise  powder  cohesivity  and  ease  of de-agglomeration.  Seven  inhaled  drug/excipient  pow-
ders  (beclometasone  dipropionate,  budesonide,  ﬂuticasone  propionate,  lactohale  300,  salbutamol  base,
salmeterol  xinafoate  and  toﬁmilast)  were  subjected  to a range  of dispersing  pressures  (0.2–4.5  Bar)
in  the  Sympatec  HELOS/RODOS  laser  diffractometer  and  particle  size  measurements  were  recorded.
Particle  size-primary  pressure  data  were  used  to determine  the  pressures  required  for complete  de-ohesion
nhalation
e-agglomeration
agglomeration.  The  latter  were  employed  as an  index  of  the  cohesive  strength  of  the  powder  (critical
primary  pressure;  CPP),  and  the  curves  were  modelled  empirically  to derive  the  pressure  required  for
50%  de-agglomeration  (DA50).  The  powders  presented  a range  of  CPP  (1.0–3.5  Bar)  and DA50 (0.23–1.45
Bar)  which  appeared  to be  characteristic  for  different  mechanisms  of powder  de-agglomeration.  This
approach has  utility  as  a rapid  pre-formulation  tool  to measure  inherent  powder  dispersibility,  in order
to direct  the  development  strategy  of  DPI  products.
© 2013 Elsevier B.V. Open access under CC BY license.. Introduction
Drug deposition within the respiratory tract is dependent on the
elivery of particles with an aerodynamic size of <5 m (Shekunov
t al., 2003; Usmani et al., 2005). The intrinsic cohesivity of such
ne and often irregularly shaped particles means that there is a
endency for particles to agglomerate (Adi et al., 2011). Micronised
rug particles are therefore often formulated with large carrier par-
icles as a means of aiding powder dispersion (Telko and Hickey,
005). During delivery it is essential that attractive drug–drug
cohesive) and drug–carrier (adhesive) forces are overcome and
articles are restored to their primary de-agglomerated state (Telko
nd Hickey, 2005). Although device and patient factors affect de-
gglomeration, the inherent dispersibility of the powder is a major
actor dictating the ease of agglomerate dispersal and hence the
elivered dose. Any imbalance of the cohesive and adhesive forces
ay  adversely affect de-agglomeration, resulting in poor aerosoli-
ation of the powder formulation (Begat et al., 2004b).
∗ Corresponding author. Tel.: +44 01707 285904; fax: +44 01707 284506.
E-mail address: d.murnane@herts.ac.uk (D. Murnane).
378-5173 © 2013 Elsevier B.V.  
ttp://dx.doi.org/10.1016/j.ijpharm.2013.02.034
Open access under CC BY license.The ease of de-agglomeration of powders may  be predicted
using indirect methods that measure inter-particulate forces. These
include highly technical single-particle techniques such as atomic
force microscopy (AFM) (Jones et al., 2008; Begat et al., 2004a)  and
bulk techniques such as inverse gas chromatography (IGC) (Das
et al., 2009c; Jones et al., 2012; Tong et al., 2006). AFM only meas-
ures a small proportion of the powder and provides potentially poor
representation of bulk properties (Bunker et al., 2005), while IGC
requires large quantities of material and long analysis times. Spe-
cially designed de-agglomeration rigs allow agglomerate break-up
to be studied under controlled levels of turbulence or impaction,
but need to be used in tandem with a particle size spectrometer
or cascade impactor (Kurkela et al., 2008; Voss and Finlay, 2002).
Impactor methods measure aerosol dispersion directly; the emit-
ted dose provides an index of powder entrainment, and the ﬁne
particle mass is indicative of de-agglomeration efﬁciency (Louey
et al., 2006). Although impactor methods are excellent for the
quality control testing of inhalation products, the analytical proce-
dures involved are labour-intensive and time consuming, making
the methods unsuitable for rapid screening of powder formula-
tion dispersibility during the early stages of product development
(Marriott et al., 2006).
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Dry dispersion laser diffraction (LD) is increasingly used to study
owder de-agglomeration. When powder is delivered to the sizer
rom a static bed, the powder is subjected to minimal disturbance to
he powder structure and an assessment of inherent dispersibility
an be made. Pressure titration, whereby size measurements are
ade under different levels of dispersing shear, is a requirement of
ethod development for LD particle sizing in the dry state to deﬁne
hose instrument parameters that provide accuracy and precision
f sizing measurements (ISO 13320: 1990). Under well-controlled
ispersing conditions, changes in the measured particle size dis-
ribution (PSD) of an aerosolised plume provide an indication of
gglomerate strength and degree of de-agglomeration (Adi et al.,
006; Ghoroi et al., 2012). Despite never having been substanti-
ted in a systematic study of pharmaceutical powders, the gradient
f measured particle size over a dispersion pressure/airﬂow range
as been suggested as an indicator of powder dispersibility (Adi
t al., 2006, 2008; Chiou et al., 2008; Ghoroi et al., 2012; Kaye
t al., 2009). Titration experiments have been conducted for this
urpose, but studies have not been validated using a wide range of
ample powders nor have they involved the generation of standard-
sed parameters for describing de-agglomeration. Where titration
ata have been related more fully to aerosolisation parameters
e.g. Behara et al., 2011a,b; Chiou et al., 2008) the studies have
etermined the particle size of the powders following actuation
rom either inhaler devices or dry powder dispersers, which con-
ribute themselves to the de-agglomeration of the powder under
nvestigation. During the early stages of inhaled product develop-
ent, information is required about the fundamental dispersion
ehaviour of the drug powder in order to guide formulation and
evice designs. If dry dispersion LD were qualiﬁed as a technique for
easuring particle size-dispersing pressure curves in a systematic
anner, for powders delivered from a static bed, this would allow
he inherent dispersibility of dry powders to be assessed reliably in
he absence of device/disperser effects.
The aim of this work was to develop a rapid method to quan-
ify the de-agglomeration of dry powders from a static bed as a
easure of inherent powder dispersibility. An optimised method-
logy based on LD was developed, standardised and used to
easure particle size-dispersing pressure titration curves for a
umber of inhaled drug/excipient powders. These data were used
o derive parameters indicative of powder cohesivity and ease of
e-agglomeration.
. Materials and methods
.1. Materials
The inhalation powders used in the study were beclometa-
one dipropionate (BDP; Pharm Dev Europe, GWRD, BN. WC60329),
udesonide (Bud; LGM Pharma, USA, BN. U0015/1V040), ﬂuticas-
ne propionate (FP; LGM Pharma, USA, BN. 458763), Lactohale 300
LH300; Frieslands Foods, Domo, The Netherlands, BN. 6125224/S),
albutamol base (SB; Pharm Dev Europe, GWRD, BN. WC46269),
almeterol xinafoate (SX; Vamsi Labs, India, BN. SX-0081010), and
oﬁmilast (Tof; Pﬁzer Ltd, PGRD Sandwich Laboratories, UK). Cyclo-
exane was purchased from VWR  International (France), methanol
nd sorbitan monooleate 80 (Span 80) were from Sigma Aldrich Ltd
UK), hexane was from Fisher Scientiﬁc (Loughborough, UK), and
pan 85 and Tween 80 were from Merck (Schuchardt, Germany).
.2. Methods.2.1. Particle size measurements by liquid dispersion laser
iffraction
Laser diffraction particle sizing was carried out using a Malvern
astersizer X (Malvern Instruments Ltd, UK) ﬁtted with a 100 mmarmaceutics 447 (2013) 124– 131 125
focal length lens (0.5–180 m)  and an MS7  magnetically stirred
cell. Saturated solvent dispersants were prepared by sonicating
for 30 min followed by overnight stirring. Approximately 1 mg
of powder was  added to 2 mL  ﬁltered dispersant (0.2 m cellu-
lose acetate syringe ﬁlter, Gema Medical S.L., Spain) and sonicated
(Sonicleaner, DAWE, Ultrasonics Ltd, USA). A background read-
ing was  taken and the suspension was added to the sample
cell until the obscuration was ∼10–30%. Following equilibration
(30–60 s), ten individual measurements were taken for n = 3 sam-
ples to obtain particle size measurements (Dv10, Dv50, and Dv90,
corresponding to the particle size below which 10%, 50% and
90% of the particles by volume are smaller than, and the volume
mean diameter, VMD, the volume weighted mean particle size
of the sample) calculated using Fraunhofer theory. A summary of
the dispersant, sonication time, stir setting, sweeps, presentation
and equilibration time used to size each powder are provided in
Table 1.
2.2.2. Scanning electron microscopy (SEM)
Powder samples were transferred onto glass cover-slips placed
on adhesive carbon tabs (G3347N, Agar Scientiﬁc, Essex, England)
which were mounted onto aluminium pin stubs (0.5 in.; G301, Agar
Scientiﬁc Ltd, Essex, England). Samples were sputter coated with
gold for 2 min  to achieve a thickness of approx. 15–20 nm using
a K550X sputter coater (Emitech, Quorum Technologies Limited,
West Sussex, England). Particle morphology was  viewed using a
Quanta 200F ﬁeld emission scanning electron microscope (FEI UK
Ltd, Cambridge, England) operated at 10 kV in low vacuum mode
and a working distance of 10 mm.
2.2.3. Particle size measurements by dry dispersion laser
diffraction
Particle size measurements were made using a Sympatec
HELOS/RODOS (Sympatec GmbH, Clausthal-Zellerfel, Germany)
employing the rotary feeder and R3 lens (0.9–175 m).  Powder was
hand-ﬁlled into the u-shaped groove of the rotating table to cover
a length of approximately 1 cm.  The sample passed under a plough
scraper and roller to remove any excess and was subsequently
drawn up into the dispersing line via the protruding aspiration
tube from a static bed. During sample delivery the rotating table
was maintained at a constant rotation setting of 20%. The mea-
surement was  set to trigger when the optical concentration (Copt)
exceeded 1.1% and cease when the Copt fell below 1% for 5 s (or 60 s
real time). The timebase was  100 ms  and a forced stability of ‘4’
was applied. The primary pressure (PP) was  manually set using the
adjustment valve in the range 0.2–4.5 Bar and three measurements
were taken at each pressure setting using freshly loaded powder.
PSDs (Dv10, Dv50, Dv90 and VMD) were calculated using Fraunhofer
theory and analysed in WINDOX 4.0 software. Particle size mea-
surements for a complete titration curve were made on a single
day.
2.2.4. Critical primary pressure
The pressure at which the particle size-primary pressure pro-
ﬁle reached a plateau was  considered to represent the pressure
required to overcome the interactive forces holding agglomerates
together and therefore provide a measure of the cohesivity of the
powder. The critical primary pressure (CPP) was derived by cal-
culating a difference ratio (dr) using Eq. (1),  where the Dv50 is the
geometric median diameter at a given primary pressure (mean of
n = 3 measurements), and PP1 and PP2 are two consecutive primary
pressures (PP2 > PP1). The CPP was  assigned when dr was  in the
range −0.06 < dr > 0.06 for three consecutive measurements (the
accepted coefﬁcient of variance for Dv50 values in particles of this
126 S. Jaffari et al. / International Journal of Pharmaceutics 447 (2013) 124– 131
Table 1
A summary of the liquid dispersion laser diffraction parameters used in particle sizing of the powders.
Powder Dispersant (%, w/v) Sonication time (min) Stir setting Sweeps Equilibration time (s)
BDPa 1.0% Span 80 in cyclohexane 5 3 3500 60
Budb 0.1% Span 80 in cyclohexane 15 3 3500 60
FPc 0.1% Span 80 in cyclohexane 2.5 3 3500 60
LH300d 0.1% Span 80 in cyclohexane 1 3 3500 30
SBd 1.0% Span 85 in hexane 1 3 3500 30
SXc 0.5% span 80 in cyclohexanec 5 3 2500 60
Tof  0.05% Tween 80 in 5% (v/v) methanol and water 5 5 2500 60
a Zeng et al. (2000).
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ize range when validating a particle size methodology according
o ISO 13320: 1990):
r = Dv50PP1 − Dv50PP2Dv50PP1
(1)
.2.5. Ease of de-agglomeration
A method of data analysis was developed to derive a parameter
or ease of de-agglomeration. The particle size data were nor-
alised to account for differences in the primary particle size of
ach powder. The particle size at each primary pressure (Dx) was
xpressed as a proportion of the fully dispersed particle size (DH, the
v50 measured at the highest PP) according to Eq. (2).  The degree of
e-agglomeration (DA) was  therefore a measure of the extent of de-
gglomeration achieved at any particular pressure, with complete
ispersion of the powder to primary particles at DA = 1.
A = DH
Dx
(2)
The de-agglomeration data exhibited rectangular hyperbo-
as and were empirically modelled. When ﬁtted to a linearised
reundlich equation the linearity was poor (R2 = 0.69–0.92), but
he modiﬁed Michaelis–Menten equation linearised using the
anes–Woolf approach (Fig. 1, Eq. (3))  provided an excellent ﬁt.
he maximum degree of de-agglomeration (DAmax) was  obtained
rom the asymptote degree of de-agglomeration, calculated using
he slope of the ﬁtted regression line (Fig. 1). The DA50 was  derived
rom the intercept and slope of the regression line to obtain the pri-
ary pressure required to achieve 50% de-agglomeration (Fig. 1).
he DA50 was chosen as it could be derived from the regression line
f the linearised data without further data manipulation or errors
f interpolation, such as would result from interpolation.
PP
DA
= 1
DAmax
, PP + DA50
DAmax
(3)
ig. 1. A schematic of the de-agglomeration analysis employed using beclometasone dip
s the measured Dv50 at a particular PP, DA is the degree of de-agglomeration, DA50 is the3. Results
3.1. Particle size of the powders by liquid dispersion
The liquid dispersion particle size was  measured to determine
the fully dispersed particle size in a liquid medium independent of
the dry dispersion laser diffraction technique. To maintain consis-
tency between sizers, Fraunhofer theory was used in all particle size
calculations. The results conﬁrmed that all the powders possessed
a PSD within the micron size range (Table 2), with Dv50 values ran-
ging from 1.44 ± 0.16 m for SB to 3.74 ± 0.41 m for LH300. In all
instances the Dv50 was less than 4 m and therefore of a size typical
of that used for inhaled delivery.
3.2. Particle morphology
SEM imaging further conﬁrmed that each powder was com-
posed of micron-sized particles (Fig. 2). All the powders were
agglomerated and exhibited a range of agglomerate sizes. The
agglomerates were also observed to be in association with each
other, suggesting that inter-agglomerate interactions occurred
leading to the formation of larger agglomerated structures within
the powder.
3.3. Effect of primary pressure on the particle size distribution
following dry dispersion
A shift towards smaller particle sizes was seen in the PSD for
all the powders as primary pressure increased (Fig. 3). For some
powders i.e. BDP, Bud (Fig. 3), LH300 and Tof, a small shoulder in
the curve was seen due to very ﬁne particles. This shoulder could
arise as a result of particle fracture at high dispersing pressures. SB
showed no shift and only a narrowing in the PSD (Fig. 3) indicating a
narrow distribution in particle/agglomerate sizes even under a low
ropionate (BDP) data, where DH is the Dv50 at the highest primary pressure (PP), Dx
 PP for 50% de-agglomeration and DAmax is the maximum DA.
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Table 2
The geometric particle size (Dv10, Dv50, Dv90, VMD) of the powders assessed by dry dispersion laser diffraction at 4.5 Bar primary pressure (n ≥ 3, mean ± SD) and liquid
dispersion laser diffraction (n = 3, mean ± SD).
Powder Dispersion Dv10 (m) Dv50 (m) Dv90 (m) VMD  (m) Span
BDP Dry 0.70 ± 0.00 1.65 ± 0.00 3.50 ± 0.00 1.90 ± 0.01 1.70
Liquid  1.20 ± 0.02 2.62 ± 0.24 4.75 ± 0.71 2.87 ± 0.32 1.36
Bud Dry  0.70 ± 0.00 1.74 ± 0.00 4.08 ± 0.01 2.12 ± 0.00 1.94
Liquid  1.02 ± 0.02 2.17 ± 0.03 4.39 ± 0.03 2.49 ± 0.02 1.55
FP Dry  0.88 ± 0.03 2.44 ± 0.11 5.75 ± 0.23 3.01 ± 0.13 1.90
Liquid 1.25 ±  0.01 2.81 ± 0.03 5.18 ± 0.13 3.06 ± 0.05 1.40
LH300 Dry 0.91 ±  0.01 3.32 ± 0.01 8.26 ± 0.02 4.06 ± 0.01 2.22
Liquid  1.78 ± 0.08 3.74 ± 0.41 6.57 ± 1.14 4.02 ± 0.52 1.28
SB Dry  0.60 ± 0.01 1.07 ± 0.01 2.17 ± 0.01 1.25 ± 0.01 1.46
Liquid  0.78 ± 0.08 1.44 ± 0.16 2.51 ± 0.29 1.57 ± 0.17 1.19
SX Dry  0.67 ± 0.00 1.51 ± 0.03 3.47 ± 0.03 1.84 ± 0.01 1.83
Liquid  0.81 ± 0.01 2.05 ± 0.12 4.33 ± 0.25 2.39 ± 0.18 1.71
Tof Dry  1.13 ± 0.02 2.78 ± 0.02 5.48 ± 0.01 3.08 ± 0.01 1.56
Liquid  0.87 ± 0.01 2.62 ± 0.02 4.98 ± 0.06 2.81 ± 0.02 1.57
Fig. 2. Scanning electron micrograph images of beclometasone dipropionate (BDP), budesonide (Bud), ﬂuticasone propionate (FP), lactohale 300 (LH300), salbutamol base
(SB),  salmeterol xinafoate (SX) and toﬁmilast (Tof) at 10,500× magniﬁcation.
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Fig. 3. The particle size distribution of budesonide (Bud), salbutamol base (SB), and
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Fig. 4. The particle size-primary pressure (PP) proﬁles of the inhaled powders
measured by Sympatec HELOS/RODOS dry dispersion laser diffraction (mean ± SD,
n  = 3). Note: the proﬁles of beclometasone dipropionate (BDP) and budesonide (Bud)
overlap; the inset graph is the particle size-primary pressure proﬁle of salmeterol
and most cohesive powders, respectively (Table 3). It was  there-
fore possible to rank the powders from low to high cohesivity as
follows: SB < Bud = LH300 < BDP < FP = Tof < SX.
Table 3
The linearity (R2), primary pressure for 50% de-agglomeration (DA50), maximum
degree of de-agglomeration (DAmax) and critical primary pressure (CPP) of the pow-
ders deduced from dry dispersion laser diffraction.
Powder R2 DA50 (Bar) DAmax CPP (Bar)
BDP 0.9990 0.44 1.11 2.5
Bud  0.9995 0.32 1.08 2.0
FP  0.9049 1.15 1.13 3.0a
LH300 0.9997 0.23 1.06 2.0
SB  0.9979 0.25 1.06 1.0
SXb 0.9711 1.45 1.35 3.5
Tof  0.9964 0.28 1.07 3.0almeterol xinafoate (SX) at 0.5, 1.0, 2.0 and 4.0 Bar primary pressure measured
y  Sympatec HELOS/RODOS dry dispersion laser diffraction (n = 1 measurement
hown).
evel of dispersing pressure (i.e. a powder which readily disperses).
P and SX (Fig. 3) demonstrated bimodal distributions at low pri-
ary pressures, which were attributed to the powder containing a
opulation of readily dispersible ﬁne particles/agglomerates and a
econd population of larger cohesive agglomerates. At high primary
ressures a shift of the ﬁne particle peak occurred corresponding
o an increase in the ﬁne particle fraction (FPF) of smaller particles
nd a tendency to eliminate large agglomerates.When the Dv50 was plotted as a particle size-primary pressure
roﬁle (Fig. 4) all the powders exhibited a reduction in particle size
ntil a plateau size was reached. The plateau particle size was  com-
arable to that measured using liquid dispersion, indicating thatxinafoate (SX) which had the largest measured size at the lowest PP (data point
omitted from main graph).
complete dispersal was  achieved. The pre-plateau proﬁles of the
particle size-primary pressure curves differed, indicating powder-
speciﬁc de-agglomeration behaviour (Fig. 4). Traditional pressure
titration analysis during validation of particle sizing methods fails
to investigate this pre-plateau behaviour despite the wealth of
information, pertinent to inhaled product development, which it
can offer regarding the de-agglomeration process. The high degree
of variability of SX and FP particle size at low dispersing pressures
(i.e. large standard deviations) indicated heterogeneity in agglom-
erate size and strength in these powders. SB had the smallest
and SX the largest agglomerate size at low dispersing pressure.
Some of the powders reached their plateau particle size at low
primary pressures, e.g. SB, whereas for other powders complete
de-agglomeration required higher dispersing pressures e.g. FP and
Tof.
3.4. Cohesivity and ease of de-agglomeration
The CPP indicated that the powders varied in their cohesive
strength from 1.0 Bar for SB to 3.5 Bar for SX indicating the leasta Measured size unchanged for 2 consecutive dispersing pressures only, 3.0 and
3.5 Bar.
b Particle size data for the lowest PP (i.e. 0.3 Bar) omitted due to poor linearity
with these data included (R2 = 0.4532).
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Fig. 5. The de-agglomeration proﬁles of the inhaled powders beclometasone dipro-
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tionate (BDP), budesonide (Bud), ﬂuticasone propionate (FP), lactohale 300 (LH300),
albutamol base (SB), salmeterol xinafoate (SX) and toﬁmilast (Tof) measured by
ympatec HELOS/RODOS dry dispersion laser diffraction (mean ± SD, n = 3).
Distinct de-agglomeration proﬁles were obtained for the pow-
ers following normalisation (Fig. 5). Linear transformations
rovided excellent ﬁts for all the powders (R2 > 0.99 except for SX
2 = 0.97 and FP R2 = 0.91, Table 3). Calculated DAmax values reached
.0, as would be expected for complete dispersion of the pow-
ers based on the normalisation data analysis approach adopted
Table 3). The DAmax also provided a further measure of the degree
f ﬁt of each data set to the model. The theoretical DAmax was  1.0,
nd powders showing the greatest deviation in this parameter (i.e.
X and FP) also had the poorest linearity owing to them possessing
he largest variability (i.e. highest standard deviations) for replicate
article size measurements at low dispersing pressures (Fig. 4). The
A50, a measure of the relative ease of powder de-agglomeration
Table 3, Fig. 5), indicated that SX and FP de-agglomerated the least
eadily (DA50 = 1.45 and 1.15 Bar, respectively) and Bud, LH300, SB
nd Tof dispersed very readily (DA50 = 0.32, 0.23, 0.25, 0.28 Bar,
espectively). BDP was an intermediate disperser (DA50 = 0.44 Bar).
. Discussion
The ultimate goal of dry powder inhaler product development is
o maximise the fraction of powder emitted upon inhalation by the
atient which is of a respirable size (<5 m).  This requires the pow-
er to be readily ﬂuidisable and dispersible from a static powder
ed. The formulation development process requires a knowledge of
he de-agglomeration behaviour of the bulk micronised material,
n order to select the required formulation components and man-
facturing approach, to overcome the inherently cohesive nature
f the powders. The aim of this work was to develop a rapid and
ystematic laser diffraction-data analytical method to characterise
he de-agglomeration behaviour of potentially inhalable powders.
The liquid dispersed particle size (Table 2) and SEM images
Fig. 2) conﬁrmed that the powders were micronised and of a size
uitable for inhaled delivery, each having a Dv50 less than 4 m.
hese particle sizes corresponded with those obtained using dry
ispersion under high primary pressure, verifying that complete
e-agglomeration of the particles occurred under these conditions.
lthough there were signiﬁcant differences (p < 0.05, unpaired stu-
ents t-test) between the sizes measured using dry and liquid
ispersion (except for LH300 and Tof), the absolute magnitude of
he differences was small. For example, SX was found to have aarmaceutics 447 (2013) 124– 131 129
Dv50 of 2.05 ± 0.12 m and 1.51 ± 0.03 m in the liquid and dry
dispersed state, respectively (Table 2). The dry dispersion size was
consistently smaller than the liquid dispersed size; this may  arise
from high dispersing pressures in the Sympatec causing a degree of
particle attrition/erosion due to high gas velocities and impactions
in the dispersing line (Leschonski et al., 1984; Ghoroi et al., 2012).
Differences in particle size can also arise as a consequence of the
use of different laser diffractometers and techniques. These include
the speciﬁc numerical algorithm used to analyse diffraction data
(Etzler and Deanne, 1997), the potential for dispersion in a liquid
to alter the particle shape, volume, and dissolution characteristics
of the sample, and also the orientation of particles in the sample
cell (Berthold et al., 2000).
DPI devices generally require powder de-agglomeration to
occur under relatively low dispersion forces (Shekunov et al.,
2003). When using low primary pressures for dry dispersion
sizing, agglomerates are often present and are measured in tan-
dem with primary particles. The Dv50 of the powders ranged
from 21.35 ± 1.52 m for SX to 1.86 ± 0.03 m for SB at 0.3 Bar
dispersing pressure. The powders therefore had different tenden-
cies for agglomeration and different agglomerate strengths under
equivalent low level shear conditions. For example, SB consisted
predominantly of individual particles and small SB–SB agglomer-
ates whereas SX consisted of large SX–SX agglomerates. Large SX
agglomerates have been reported at low dispersing pressures, and
are associated with low FPFs and high throat and pre-separator
deposition following aerosolisation into cascade impactors (Adi
et al., 2008; Shekunov et al., 2003). Highly cohesive powders tend to
entrain as large agglomerates (Shur et al., 2008; Tuley et al., 2008),
and the high tensile strength (which may  be associated with large,
densely packed agglomerates) requires high levels of dispersing
shear to overcome inter-particulate interactions (Adi et al., 2006).
Although the agglomeration state at low primary pressures cannot
in isolation be used as an indicator of fundamental dispersibility,
it allows for a qualitative distinction between powders of different
cohesivity and structure following the application of low levels of
shear.
The shape of the particle size-primary pressure proﬁle pro-
vided a mechanistic insight into the de-agglomeration process. For
example, the rapid drop in the Dv50 of SB under the application
of a dispersing pressure, and rapid attainment of the plateau par-
ticle size, indicated efﬁcient de-agglomeration to near complete
agglomerate dispersal occurring very readily under the application
of shear. However, for FP, the drop in the Dv50 was more progressive
suggesting a more gradual de-agglomeration process. Previously,
ﬂat gradients in particle size-dispersing shear proﬁles have been
attributed to powders showing little agglomeration and more efﬁ-
cient dispersion (Adi et al., 2006; Begat et al., 2004b; Ghoroi et al.,
2012; Kaye et al., 2009). By using multiple dispersing pressures
over a wide pressure range, and testing a number of powders,
it is apparent that the entire curve and not solely the gradient
must be considered. For example, when the complete curve was
empirically modelled, FP was  shown to disperse less readily than
SB. Furthermore, SX and FP were found to both have poor disper-
sibility despite having different particle size-dispersing pressure
proﬁles. The proﬁle can also provide insight into powder struc-
ture; for example, high standard deviations were obtained in the
measured agglomerate size at each dispersing pressure for FP. This
highlighted agglomerate size heterogeneity during dispersion, such
that under a given level of shear there will be mixed populations
of agglomerate and de-agglomerated particle sizes. This may  have
implications for the achievable ﬁne particle dose, and its repro-
ducibility following delivery, and therefore knowledge of this will
allow for rational formulation/delivery approaches.
Inter-particulate cohesive forces are difﬁcult to characterise
due to heterogeneity in particle properties such as size, shape,
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urface area and morphology (Telko and Hickey, 2005). They are
lso inﬂuenced by powder packing/tensile strength (Shur et al.,
008), external factors such as forces experienced during hand-
ing (Podczeck et al., 1994) and relative humidity (Das et al.,
009a,b). The CPP, derived from the particle size-dispersing pres-
ure curve, reﬂects the dispersing pressure required to overcome
he cohesive interactive forces between particles, and is deter-
ined by the most cohesive agglomerates which resist break-up
t low pressures. For full de-agglomeration to occur, sufﬁcient
nergy must be provided to overcome these most cohesive forces.
he CPP values revealed differences between the powders in the
agnitude of inter-particulate forces of the most cohesive parti-
les/agglomerates (Table 3) allowing the powders to be ranked, and
urther identifying that different formulation/device approaches
ould be necessary to achieve complete de-agglomeration of these
owders. A qualitative interpretation of the particle size-dispersing
tress titration curves presented by Shekunov et al. (2003) suggests
hat SX generated from precipitation in supercritical ﬂuids (S-SX)
ould have a lower CPP than micronised SX (M-SX). S-SX parti-
les also had lower surface energy and generated higher FPFs than
-SX (Shekunov et al., 2003). The CPP would therefore provide a
urther parameter, obtainable in a rapid and straightforward man-
er, indicating that lower dispersing stresses are required for these
articles to achieve de-agglomeration.
The DA (degree of de-agglomeration) was calculated at every
ispersing pressure in order to construct de-agglomeration pro-
les. At low dispersing pressures e.g. 0.3 Bar, the DA of the powders
as low (e.g. DA = 0.30 ± 0.02 for FP and DA = 0.07 ± 0.01 for SX).
 dispersing pressure of 0.1 Bar is approximately equivalent to
he viscous shear stress (S) across some DPI devices such as the
lickhaler (Shekunov et al., 2003). The DA would therefore pre-
ict that a signiﬁcant proportion of the powder (e.g. >30% for FP)
ould remain agglomerated and therefore be unavailable for depo-
ition in the target regions of the lungs following delivery. When
ized following actuation from an inhaler device, signiﬁcant lin-
ar correlations have been observed between laser diffraction and
ascade impactor FPFs (Marriott et al., 2006; Martin et al., 2006;
eng et al., 2006). The DA can therefore serve as a useful aid in the
evelopment of dry powder inhaler products by providing a rapid
ndication of the formulation and device characteristics that may
e required, based on the inherent dispersibility of the powder, in
rder to overcome cohesive forces and achieve the optimal FPF.
The parameter DA50, the dispersing pressure for 50% de-
gglomeration, provides a measure of how readily a powder
isperses. The value was derived from the intercept and slope
f the regression line of the linearised de-agglomeration pro-
les, and therefore takes into account the shape of the individual
e-agglomeration curve. Being directly determined from linear
egression parameters (gradient and intercept), the use of the DA50
voids errors of interpolation which would be achieved with other
ndices (e.g. 10th percentile). The powders could be characterised
nto those that were poor (SX and FP, DA50 = 1.45 and 1.15 Bar,
espectively), intermediate (BDP DA50 = 0.44 Bar) and good (Bud,
H300, SB, Tof, DA50 = 0.32, 0.23, 0.25, 0.28 Bar, respectively) dis-
ersers.
Together, the shape of the particle size-primary pressure proﬁle,
he CPP and DA50 values allow the de-agglomeration mechanisms
f the powders to be postulated. The absolute difference between
he DA50 and the CPP can be used to estimate the degree of
eterogeneity in cohesive forces of the sample powder. A low
PP and DA50 were obtained for LH300, SB and Bud, and resulted
n a powder that dispersed very readily, and de-agglomerated
ompletely, under a range of shear stresses. The PSDs of these
owders were mono-model, consistent with low cohesive forces
etween the particles and ﬂuidisation via an erosion mechanism,
here a stream of de-agglomerated particles are continuallyarmaceutics 447 (2013) 124– 131
entrained into the airﬂow (Shur et al., 2008; Tuley et al., 2008). In
contrast, when CPP and DA50 were both large, e.g. SX and FP, an
explosive de-agglomeration is indicated. At low shear the powders
undergo very little dispersion, due to the entrainment of large
agglomerates (Shur et al., 2008; Tuley et al., 2008), some of which
are so tightly associated that a bi-modal PSD is observed indicative
of a distinct population of tightly associated agglomerates. When
higher levels of shear, equal to or greater than the CPP, are applied,
instantaneous de-agglomeration to primary particles occurs as the
inter-particulate forces are overcome.
One of the powders, Tof, had a high CPP but a low DA50. This
may  suggest heterogeneity in the magnitude of inter-particulate
forces as some powder agglomerates will break-up readily (hence
a low DA50) but others will require a much higher dispersing
pressure (hence a high CPP) for de-agglomeration. Powders with
inter-particulate force homogeneity would conversely have simi-
lar DA50 and CPP values, with complete dispersion of agglomerates
occurring upon the application of the appropriate level of shear able
to overcome intra-agglomerate interactive forces.
A key advantage of the laser diffraction technique as developed
and described in this study is therefore its ability to account for
powder heterogeneity, and in doing so provide a more accurate
representation of powder properties compared to many existing
techniques. Single particle techniques such as AFM can provide use-
ful insights e.g., budesonide has been reported to display stronger
cohesive interactive forces than lactose (Begat et al., 2004a),
whereas those of salmeterol xinafoate and ﬂuticasone propionate
are indicated to be of comparable magnitude (Young et al., 2004).
However, since AFM by its nature can only employ a small num-
ber of isolated particles, then extrapolation of the results to the
aerosolisation behaviour of a powder bed, where the bulk cohe-
sive properties of the powder are clearly important, should only be
effected with caution. For example, if only the most cohesive par-
ticles are sampled, where a distribution of particles is likely due to
inter- and intra-batch variability in properties (Feeley et al., 1998;
Price, 2011), there may  be an overestimation of the cohesive force
of a bulk powder.
Techniques such as IGC, when using traditional inﬁnite dilution,
probes only the most active surface sites and in a similar manner
to AFM can be misleading with regards to overall powder cohesive
strength; reported values in the literature can vary e.g. the disper-
sive surface energy (D) of SX is 41–48 mJ  m−2 (Das et al., 2009c;
Tong et al., 2002). Finite dilution is able to take into account surface
heterogeneity but analysis is lengthy. Differences in the distribu-
tion of high energy sites have been identiﬁed (Tong et al., 2002;
Das et al., 2012). Furthermore, heterogeneity in particle proper-
ties leading to non-homogenous powder strength distributions has
been attributed to different de-agglomeration behaviours between
lactose samples (Das et al., 2012).
Being a bulk measurement technique, dry dispersion LD, if
conducted within a controlled environment, is therefore able to
account for every factor which may  inﬂuence de-agglomeration,
including particulate, bulk, and external factors. Furthermore, there
is little powder manipulation prior to analysis, which results in
minimal disturbance to the powder structure/packing, and the
analysis times are short. These advantages provide a convenient,
accessible and highly relevant tool in powder characterisation and
the necessary preceding step in formulation development.
5. ConclusionThe de-agglomeration behaviour of a number of chemically dis-
tinct micronised powders for inhalation was evaluated using a dry
dispersion laser diffraction technique. The bulk powders were char-
acterised with respect to their cohesive strength (CPP) and ease of
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e-agglomeration (DA50). The relative CPP and DA50 enabled pow-
er structure and de-agglomeration mechanisms to be postulated.
 strong feature of the approach is the extraction of meaning-
ul parameters from bulk powders rather than the generation of
escriptors relating to individual particles, thereby incorporating
owder heterogeneity effects which may  be lost through the use
f single particle measures such as AFM. The method also allowed
or rapid analysis times with little powder manipulation to dis-
urb powder structure/packing, which compares favourably with,
or example, IGC. The measurements also take into account all
ypes of interactive force and their heterogeneity, using a single
ethodological approach. The ability to characterise the pow-
ers independently of any formulation or device distinguishes the
ethod as a powder screening tool for inherent powder dispersi-
ility that may  be of use in a variety of pharmaceutical applications.
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